TASER (TASR) Finally Has a Real Competitor - Oppenheimer

October 5, 2016 9:26 AM EDT
Get Alerts TASR Hot Sheet
Price: $25.23 --0%

Rating Summary:
    4 Buy, 5 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade TASR Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Oppenheimer analyst Andrew Uerkwitz notes TASER International (NASDAQ: TASR) finally has real competitor after Vievu landed the NYPD contract, which will make it more competitive.

Uerkwitz commented, "We've had a chance to review the Vievu-NYPD contract. With 4,000 agencies and approximately 50,000 cameras in use, Vievu (private) has been a formidable competitor to TASER for some time and even beat TASER to the body camera opportunity (first camera shipped in 2007). But with only two top-50 agency wins (neither fully deployed), the company has struggled to appear on investor radars. That changed on Friday when it was announced that NYPD (~34,000 agents strong) chose Vievu as its body camera/evidence management partner for the agency's ~1,000 body camera trial. We see this win as a cornerstone for Vievu and would expect it to be more competitive to TASER (80% of major cities) for future large city deals. The economics are lower than what we've typically seen, but it's not out of the ordinary to offer aggressive pricing to larger agencies (TASER's London Met body camera deal comes to mind). So we do not expect to see a "race to the bottom" in the body camera/evidence management space."

The firm reiterated a Perform rating on TASR.

For an analyst ratings summary and ratings history on TASER International click here. For more ratings news on TASER International click here.

Shares of TASER International closed at $23.71 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Hot Comments, Trader Talk

Related Entities

Andrew Uerkwitz

Add Your Comment